Aspirin/phosphatidylcholine

Drug Profile

Aspirin/phosphatidylcholine

Alternative Names: ASA-PC; Aspirin-PC; PL-2100

Latest Information Update: 14 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas System
  • Developer PLx Pharma
  • Class Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Cytoprotectives; Glycerophospholipids; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Fever; Myocardial infarction; Pain; Stroke

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top